CN108210575A - 一种治疗下尿路感染的中药组合物凝胶剂的制备方法 - Google Patents
一种治疗下尿路感染的中药组合物凝胶剂的制备方法 Download PDFInfo
- Publication number
- CN108210575A CN108210575A CN201810211920.6A CN201810211920A CN108210575A CN 108210575 A CN108210575 A CN 108210575A CN 201810211920 A CN201810211920 A CN 201810211920A CN 108210575 A CN108210575 A CN 108210575A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- concentrating
- selfheal
- dandelion
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 208000019206 urinary tract infection Diseases 0.000 title claims abstract description 21
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 70
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 69
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 69
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 68
- 235000008113 selfheal Nutrition 0.000 claims abstract description 68
- 241001116757 Pyrrosia lingua Species 0.000 claims abstract description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 196
- 239000000706 filtrate Substances 0.000 claims description 87
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 70
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 68
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 68
- 241000245665 Taraxacum Species 0.000 claims description 67
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 63
- 238000001914 filtration Methods 0.000 claims description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 244000292697 Polygonum aviculare Species 0.000 claims description 50
- 235000006386 Polygonum aviculare Nutrition 0.000 claims description 50
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 46
- 241001106477 Paeoniaceae Species 0.000 claims description 45
- 235000011477 liquorice Nutrition 0.000 claims description 45
- 230000002829 reductive effect Effects 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 11
- 230000008961 swelling Effects 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 9
- 239000003906 humectant Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 38
- 230000027939 micturition Effects 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 12
- 238000009472 formulation Methods 0.000 abstract description 4
- 241000208671 Campanulaceae Species 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 210000003708 urethra Anatomy 0.000 abstract description 2
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 240000003582 Platycodon grandiflorus Species 0.000 description 57
- 238000001035 drying Methods 0.000 description 37
- 239000000843 powder Substances 0.000 description 31
- 238000002156 mixing Methods 0.000 description 27
- 241000736199 Paeonia Species 0.000 description 25
- 238000000034 method Methods 0.000 description 25
- 239000008187 granular material Substances 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 13
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 12
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 12
- 229940010454 licorice Drugs 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 235000017443 Hedysarum boreale Nutrition 0.000 description 10
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 241000025505 Pyrrosia Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 235000006751 Platycodon Nutrition 0.000 description 6
- 201000003146 cystitis Diseases 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 229930189914 platycodon Natural products 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 208000006750 hematuria Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000003809 water extraction Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 208000033809 Suppuration Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- -1 glycyrrhiza polysaccharide Chemical class 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 229960004274 stearic acid Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000000143 urethritis Diseases 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 235000010674 Prunella vulgaris Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000934878 Sterculia Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 201000005661 acute cystitis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 239000000231 karaya gum Substances 0.000 description 2
- 229940039371 karaya gum Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 239000005434 MCC/mannitol excipient Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010050822 Suprapubic pain Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229930189407 platycodin Natural products 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000036593 pulmonary vascular resistance Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗下尿路感染的中药组合物及其制备方法。该中药组合物包含萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草按一定重量配比配置而成。它可以被制成任何一种常规制剂。本发明中药组合物具有清热解毒,利湿通淋的功效,用于湿热下注证,症见尿频、尿急、尿痛、尿道灼热;舌红,苔薄黄,脉滑数;下尿路感染见上述症状者。
Description
技术领域
本发明涉及一种治疗下尿路感染的中药组合物及其制备方法,属于中药的技术领域。
背景技术
下尿路感染是指膀胱和尿道由细菌感染引发的炎症病变。又有膀胱炎、尿道炎之称。膀胱炎又分为急性膀胱炎和复发性膀胱炎。下尿路感染几乎全部为继发于泌尿系及泌尿系外的病变,而绝大多数是由革兰氏阴性菌引致,女性发生率是男性的10倍。
临床表现为:(1)急性膀胱炎、尿道炎的典型症状有排尿烧灼感或疼痛,尿急和尿频,耻骨区痛,脓尿或血尿。严重血尿多见于女性患者;(2) 全身症状主要为发热、乏力。如伴见腰背痛、恶寒、发热、恶心呕吐等全身中毒症状,表明为有肾脏感染;(3)复发性膀胱炎多见于中老年女性,表现为尿频、尿急、夜尿,膀胱充盈时耻骨上疼痛,排尿后减轻。可有镜下血尿。
目前临床上治疗下尿路感染多选用强力霉素、米诺环素、克拉霉素、阿奇霉素、加替沙星、甲砜霉素等四环素类、大环内酯类、喹诺酮类、胱胺醇类抗生素进行治疗。但这类药物对人体都有较强的毒副作用,并且容易产生抗药性,疗效并不是很理想。中医认为,下尿路感染属于中医学“淋证”、“淋浊”、等范畴,病因多因房事不洁或感染秽浊之邪,阻滞下焦,蕴结膀胱,化热化火,导致膀胱气化不利,肝郁气滞,气血瘀阻而致。病因病机在于湿热,多采用清热解毒、利湿通淋的方法以达到标本兼治的目的。同时中药复方制剂治疗此病不易产生耐药菌株,且副作用小,既简单又安全。因此研究开发治疗下尿路感染中药制剂前景广阔,经济社会效益显著。
发明内容
本发明的目的在于提供一种新的中药组合物,该组合物具有清热解毒,利湿通淋的功效,用于湿热下注证,症见尿频、尿急、尿痛、尿道灼热;舌红,苔薄黄,脉滑数;下尿路感染见上述症状者。
本发明的另一个目的是提供上述中药组合物的制备方法。
本发明是通过以下技术方案实现的:
本发明是由下述重量份的原料制成的:萹蓄3-30份、野菊花1-20份、石韦 3-30份、蒲公英1-20份、赤芍1-20份、夏枯草1-20份、桔梗1-20份、甘草1-20 份。
优选的重量份为:萹蓄5-15份、野菊花3-10份、石韦5-15份、蒲公英3-10 份、赤芍3-10份、夏枯草3-10份、桔梗3-10份、甘草3-10份。
更优选为:萹蓄8-12份、野菊花5-8份、石韦8-12份、蒲公英5-8份、赤芍4-6份、夏枯草5-8份、桔梗5-8份、甘草4-6份。
最佳优选为:萹蓄10份、野菊花6份、石韦9份、蒲公英6份、赤芍5份、夏枯草6份、桔梗6份、甘草5份。
其中,甘草是指生甘草。
中医认为,下尿路感染的病因病机的中心在于湿热,其主要症状即是明显的湿热之证。应采用清热解毒、利湿通淋的方法以达到标本兼治的目的。
该中药组合物的作用机理如下:
萹蓄:为蓼科一年生草本植物萹蓄的干燥地上部分。苦,微寒。归膀胱经。该品苦降下行,通利膀胱,苦燥又能杀虫除湿止痒,主要用于淋痛及湿疹。药理研究显示:萹蓄具有补肾、清肝明目、利尿的功能;主治淋痛、湿疹、泌尿系统感染、结石、血尿等症;现代研究表明,萹蓄具有利尿、降压、抗菌、止血等作用;煎剂20g/kg给予盐水负荷的大鼠后,尿量、钠钾排出均增加,特别是钾的排出较多,其灰分亦有同样效果。浓度为25%的全草煎剂对福氏痢疾杆菌和宋内氏痢疾杆菌皆有抑制作用。1:10浓度的煎剂对须疮癣菌、毛羊状小芽胞菌有抑制作用。40%水煎剂对葡萄球菌、绿脓杆菌、皮肤真菌均有抑制作用。
野菊花:为菊科植物野菊、北野菊或岩香菊的头状花序。味辛、苦。归肺、肝经。具有清热解毒,疏风平肝的功效,用于疔疮,痈疽,丹毒,湿疹,皮炎,风热感冒,咽喉肿痛,高血压病等。药理研究表明,野菊花水提物与挥发油均具有较强的抑菌和抗病毒活性。药理研究:野菊花水提物对金黄色葡萄球菌、大肠埃希菌、白喉杆菌、变形杆菌、伤寒杆菌、绿脓假单胞菌、福氏志贺菌有较强的抑制作用,而对肺炎链球菌的抑制作用较弱;野菊花水提物体外抑菌试验表明:对脲原体生长抑制作用明显。水提取物具有抗病毒活性。
石韦:为水龙骨科植物石韦,庐山石韦、毡毛石韦、有柄石韦、北京石韦或西南石韦的叶。味苦、甘,性凉。归肺、膀胱经。具有利水通淋,清肺泄热的功效,用于治淋痛,尿血,尿路结石,肾炎,崩漏,痢疾,肺热咳嗽,慢性气管炎,金疮,痈疽等。药理研究文献表明:石韦煎剂用平板打洞法、对金黄色葡萄球菌及变形杆菌有抑制作用;水溶性的异芒果甙具有显着的抗单纯疱疹病毒作用。药理研究表明:石韦的药理作用为具有利尿通淋,清热止血的功效,用于热淋、血淋、石淋、小便不通、淋沥涩痛。含有杧果苷和异杧果苷经药理研究证明有抑菌和抗单纯疱疹病毒、为镇咳祛痰的有效成分,绿原酸也有抗菌、兴奋中枢神经系统等作用。有柄石韦中含有(±)圣草酚7-O-β-D-吡喃葡萄糖醛酸苷和绿原酸不但含量高,而且前者具有一定的PKC抑制活性,后者具有抗菌、抗炎和抗病毒等活性。
蒲公英:为菊科植物蒲公英、碱地蒲公英或同属数种植物的干燥全草。甘,微苦,寒。清热解毒,消肿散结。主要用于上呼吸道感染,眼结膜炎,流行性腮腺炎,高血糖,乳痈肿痛,胃炎,痢疾,肝炎,胆襄炎,急性阑尾炎,泌尿系感染,盆腔炎,痈疖疔疮,咽炎,治急性乳腺炎,淋巴腺炎,瘰疠,疔毒疮肿,急性结膜炎,感冒发热,急性扁桃体炎,急性支气管炎、尿路感染等。药理实验表明:经大量研究证实,蒲公英具有广谱的抑菌作用;孙继梅等观察了蒲公英对临床常见203株分离菌的体外抑菌活性,并进行了体外最小抑菌浓度(MIC)测定。结果显示,蒲公英水煎剂对金黄色葡萄球菌、凝固酶阴性葡萄球菌、肺炎球菌、β-溶血性链球菌,肠球杆菌、大肠埃希均、肺炎克雷伯菌、枸橼酸杆菌、绿脓杆菌、流感嗜血杆菌、白色念球菌、等临床常见感染菌有抑菌活性,尤其对革兰阳性、阴性球菌有较好的抑制作用。
赤芍:为毛茛科植物芍药或川赤芍的干燥根。味苦,性微寒。归肝经。具有清热凉血,散瘀止痛的功效,可用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡等。药理学研究表明赤芍抑制血小板聚集,改善红细胞的通透性,增加红细胞对低渗张力的抗性,有一定稳定红细胞膜结构的作用。另外,赤芍总苷能明显延长大鼠和小鼠的凝血时间,并能延长电刺激大鼠颈总动脉血栓形成的时间,提示赤芍总苷通过对凝血系统和血小板功能的影响而产生抗血栓作用。赤芍是传统的活血化瘀类中药,有较强的抗动脉粥样硬化作用;该药也能扩张冠脉血管,增加冠脉血流量从而增加心肌营养性血流量;保护缺血心肌,提高心肌对低氧的耐受性;降低肺血管阻力,减轻后负荷。同时赤芍能够降低门脉高压,对微循环也有影响。赤芍具有抗炎、抗变态反应作用,清除活性氧自由基的作用,还具有滋补强壮作用,对神经系统也有一定作用。
夏枯草:为唇形科植物夏枯草的干燥果穗。性寒,味甘、辛、微苦,具有清泄肝火、散结消肿、清热解毒、祛痰止咳、凉血止血的功效,适用于淋巴结核、甲状腺肿、乳痈、头目眩晕、口眼歪斜、筋骨疼痛、肺结核、血崩、带下、急性传染性黄疸型肝炎及细菌性痢疾等。药理研究表明:夏枯草中多糖成分具有抗HSV-1、HSV-2(单纯疱疹病毒)的作用,还具有明显抗HIV-1(人类免疫缺陷病毒)的作用;马德恩通过大鼠耳肿胀、足肿胀实验表明夏枯草水煎醇沉液对早期炎症反应有显著抑制作用;秦雯通过夏枯草醇提取物对大肠杆菌抑制效果的研究,说明夏枯草对大肠杆菌有明显的抑菌效果。王放银对抗菌成分提取工艺及其抑菌效果进行了具体研究,结果表明夏枯草提取液对大肠杆菌、金黄色葡萄球菌、枯草杆菌、青霉和黑曲霉均有明显的抑菌作用。
桔梗:为桔梗科植物桔梗的干燥根部,味苦、辛,性微温。入肺经。有宣肺、祛痰、利咽、排脓、利五脏、补气血、补五劳、养气的作用。用于咳嗽痰多、咽喉肿痛、肺痈吐脓、胸满胁痛、痢疾腹痛、口舌生疮、目赤肿痛、小便癃闭。用于咳嗽痰多,胸闷不畅,咽痛,音哑,肺痈吐脓,疮疡脓成不溃。药理研究表明:桔梗具有开宣肺气,祛痰排脓之功效,具有祛痰、镇咳、抗炎、降血压、扩张血管、解热、镇痛、降血糖、抗过敏、抗肿瘤及提高免疫力等广泛的药理活性。桔梗的活性物质基础主要为三萜皂苷。桔梗皂苷能抑制iNOS和COX-2,是通过阻止NF-kB(核转录因子 KB)的活性。减少iNOS和COX-2基因表达来实现,从而达到抗炎镇痛作用;桔梗水提取可显著刺激小鼠腹腔巨噬细胞增生,抑制细胞增殖;通过抑制胰脂肪酸活性来抑制对食物脂肪的吸收作用。
甘草:为豆科植物甘草、胀果甘草或光果甘草的干燥根及根茎。味甘,性平。归心、肺、脾、胃经。具有补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药的功效,用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,腕腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性等。药理研究表明:甘草水煎剂在体外能明显抑制绿脓杆菌、变形杆菌、金黄色葡萄球菌、表皮葡萄球菌、链球菌、枯草杆菌。甘草水煎剂抑制金黄色葡萄球菌时MIC 相当于8×10-4g/L的庆大霉素;对绿脓杆菌、变形杆菌的MIC相当于 7×10-4g/L的庆大霉素;其对金黄色葡萄球菌的MIC相当于4×10-4g/L庆大霉素;对表皮葡萄球菌、枯草杆菌、甲型链球菌的MIC分别相当于2×10-4、 5X 10-4、3X 10-4g/L庆大霉素。文献报导甘草多糖有明显的抗水泡性口炎病毒、腺病毒I型、单纯疱疹病毒I型、牛痘病毒的活性。
本发明中,萹蓄、野菊花为君药,石韦、蒲公英为臣药,赤芍、夏枯草、桔梗为佐药,甘草为使药。各药物之间功效产生协同作用,为治疗下尿路感染的有效方剂。
本发明药物可以采用中药制剂的常规方法制备成任何常规的制剂,包括口服制剂,外用制剂,注射剂等。例如可以将这些原料药研成粉末混合均匀;可以将所述重量份的原料药分别加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物,或采用精制方法,例如,水提醇沉法、有机溶剂萃取法、柱层析法、二氧化碳超临界萃取法、水蒸气蒸馏法进行精制得到精提物。
在使用上述药物时,既可以采用以相当于所述重量配比的药物为原料分别净选,干燥、粉碎、混合得到符合制剂要求粒度的颗粒或粉末直接服用。也可以采用以相当于所述重量配比关系的药物为原料经过适当处理后添加药用辅料,根据需要将其制成各种制剂。由上述原料药制备成制剂的过程中,上述原料药可以采用如下方法进行处理:将所述重量份的原料药直接粉碎得药材粉末;或分别加水或不同浓度的乙醇提取或采用水提醇沉法、离心法、水蒸气蒸馏法提取得提取物;在对上述有效药用成分进行提取时可采用的具体操作和/或使用方法,既可以是以所述的各比例量的药物成分为原料,分别提取其有效药用成分后再混合的方式,也可以采用按所说比例量的各药物原料混合后再共同提取的方式。采用不同的提取手段、设备及提取时所需的理想或最佳的提取温度、溶剂用量、提取时间、提取次数等具体条件,则可根据实际情况通过试验被筛选和找到。
为了使该药物的各原料更好的发挥药效,优选对原料中的萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加水提取。但不能用于限制本发明的保护范围。
该中药组合物的制备方法为:
所述重量份的萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草单独或合并加水提取,滤过,合并滤液,适当浓缩,离心或者加乙醇使沉淀,静置,滤过,滤液减压回收乙醇,浓缩至稠膏,干燥,粉碎成细粉,即得本发明药物的活性成分。
该中药组合物的优选的制备方法具体为:
所述重量份的萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草单独或合并加8~12倍量水提取1~4次,每次0.5~3小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~1.15,加乙醇使含醇量达50~90%,静置,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,即得本发明药物的活性成分。
其中,
加水提取的条件优选为:加10倍量水提取3次,每次1小时;
加乙醇沉淀的条件优选为:加乙醇使含醇量达70%,静置12小时。
本发明中药组合物的制备方法还可以为:
所述重量份的萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草单独或合并加8~12倍量水提取1~4次,每次0.5~3小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~1.10,离心,上清液继续浓缩至稠膏,干燥,粉碎成细粉,即得本发明药物的活性成分。
其中,
加水提取的条件优选为:加10倍量水提取3次,每次1小时。
以上任意一种方法制备得到的活性成分可以直接入药服用或加入药剂学上可接受的辅料按常规工艺制备成所需制剂。如可以制成常用的片剂(分散片、泡腾片、口腔崩解片、含片、咀嚼片、泡腾片)、胶囊剂(硬胶囊、软胶囊剂)、颗粒剂、丸剂(滴丸剂)、散剂等固体制剂形式的口服药物,也可以制成糖浆、口服液等液体制剂形式的口服药物;还可以制成膏剂、凝胶剂、软膏剂、巴布剂、贴膏剂、搽剂、洗剂、涂膜剂等外用制剂形式的外用药物。因此,该药物组合物中除有效成分外,还可以含有药学上可以接受的辅料。
这里所述的片剂、胶囊剂、颗粒剂等制剂的制备工艺中涉及制粒工艺的采用湿法制粒或者一步制粒。
这里所述的辅料,可以根据不同的制剂有所不同,如在片剂、胶囊剂、颗粒剂等固体制剂中常用的稀释剂、崩解剂、赋形剂、粘合剂、润滑剂、表面活性剂、填充剂等;在糖浆、口服液等液体制剂形式中常用的表面活性剂、稀释剂、防腐剂、稳定剂、矫味剂、增稠剂、助流剂等;在凝胶剂、软膏剂等外用制剂形式中常用的药用油性基质、水性基质、防腐剂、抗氧剂、保湿剂、透皮吸收促进剂、表面活性剂等。
其常用辅料如淀粉、乳糖、糊精、糖粉、微晶纤维素、甘露醇、木糖醇、聚乙二醇、硫酸钙、磷酸氢钙、碳酸钙、改良淀粉、山梨醇、聚乙烯吡咯酮、重质碳酸镁、羧甲基纤维素钠、羟丙甲基纤维素、甲基纤维素、乙基纤维素、羧甲淀粉钠、羟丙基纤维素、聚维酮K30、白陶土、预胶化淀粉、硬脂酸镁、滑石粉、微粉硅胶、甜叶菊苷、甜菜碱、阿司帕坦、甘草甜素、糖精钠、枸橼酸、碳酸氢钠、碳酸钠、卡拉胶、琼脂、明胶、海藻酸钠、黄原胶、瓜耳豆胶、西黄耆胶、阿拉伯胶、槐豆胶、刺梧桐胶、硬脂酸、单硬脂酸甘油酯、聚丙烯酰胺、交联型聚丙烯酸钠、聚乙烯醇、卡波姆、山梨酸、山梨酸钾、羟苯乙酯、苯甲醇、尼泊金、硫柳汞、二甲基亚砜、氮酮、三乙醇胺、氢氧化钠、甘油、丙二醇、BHT、BHA、十二烷基硫酸钠、吐温类、司盘类等。
对于上面提到的制剂,其制备方法举例如下:
颗粒剂采用如下方法制备:
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~1.10,离心,上清液继续浓缩至稠膏,干燥,粉碎成细粉,加入适量辅料,混匀,湿法制粒或者一步制粒,干燥,整粒,即得颗粒剂。
片剂采用如下方法制备:
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入适量辅料,混匀,湿法制粒或者一步制粒,干燥,加入适量硬脂酸镁,混匀,压片,包衣或不包衣,即得片剂。
口服液体制剂采用如下方法制备:
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,适当浓缩,加入适量的混悬剂、调味剂、防腐剂,混匀,加水定容,滤过,分装,即得液体口服制剂。
凝胶剂采用如下方法制备:
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,加入凝胶基质、保湿剂、防腐剂,搅拌使溶解,放置,使充分溶胀,加溶剂调至全量,搅拌均匀,制成凝胶,即得凝胶剂。
软膏剂采用如下方法制备:
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,适当浓缩,备用;取硬脂酸、单硬脂酸甘油酯、十八醇、十六醇、轻质液状石蜡、中链脂肪酸甘油三酯(GTCC)、丁羟甲苯(BHT)适量,85℃加热熔融,作为油相;另取甘油、丙二醇、硬脂酸聚烃氧(40)酯、蔗糖硬脂酸酯S-15、三梨酸钾适量,加入药液和适量纯化水中溶解,加热至85℃,作为水相;将水相缓缓加入油相中,85℃保温乳化,转速为2000r/min,乳化15分钟后,继续搅拌冷却至 40℃左右,搅拌15分钟,分装,即得软膏剂。
上述制备方法仅对本发明所提制法进行列举,但不应将此理解为本发明制备方法仅仅限于上述所列举方法。
本发明以中医理论为依据,采用上述的有效药物相互配合组方,在研究并汇集历代传统名方特长的同时,结合现代科学研究的成果而成的临床验方。试验结果显示,其在治疗下尿路感染方面效果确切。
根据上述内容,在不脱离本发明基本技术思想前提下,按照本领域的普通技术知识和惯用手段,显然还可以作出其他多种形式的修改、替换和变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实施例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式:
实施例1
萹蓄1110g、野菊花666g、石韦999g、蒲公英666g、赤芍555g、夏枯草 666g、桔梗666g、生甘草555g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~ 1.10,离心,上清液继续浓缩至稠膏,干燥,粉碎成细粉,加入蔗糖、糊精、阿斯巴甜适量,混匀,一步制粒,干燥,整粒,即得颗粒剂。
实施例2
萹蓄555g、野菊花1110g、石韦555g、蒲公英1110g、赤芍333g、夏枯草 1110g、桔梗333g、生甘草1110g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~ 1.10,离心,上清液继续浓缩至稠膏,干燥,粉碎成细粉,加入乳糖、甘露醇适量,混匀,一步制粒,干燥,整粒,即得颗粒剂。
实施例3
萹蓄1665g、野菊花333g、石韦1665g、蒲公英333g、赤芍1110g、夏枯草 333g、桔梗1110g、生甘草333g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~ 1.10,离心,上清液继续浓缩至稠膏,干燥,粉碎成细粉,加入微晶纤维素、乳糖适量,混匀,一步制粒,干燥,整粒,即得颗粒剂。
实施例4
萹蓄333g、野菊花2220g、石韦333g、蒲公英2220g、赤芍111g、夏枯草 2220g、桔梗111g、生甘草2220g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入适量预胶化淀粉、二氧化硅、滑石粉,混匀,一步制粒,干燥,加入适量硬脂酸镁,混匀,压片,即得片剂。
实施例5
萹蓄3330g、野菊花111g、石韦3330g、蒲公英111g、赤芍2220g、夏枯草 111g、桔梗2220g、生甘草111g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~ 1.10,离心,上清液继续浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入羧甲基淀粉钠、微粉硅胶、微晶纤维素、交联聚维酮适量,混匀,湿法制粒,干燥,加入适量硬脂酸镁,混匀,压片,即得片剂。
实施例6
萹蓄1332g、野菊花555g、石韦1332g、蒲公英555g、赤芍666g、夏枯草 555g、桔梗888g、生甘草444g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~ 1.10,离心,上清液继续浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,一步制粒,干燥,整粒,即得颗粒剂。
实施例7
萹蓄1110g、野菊花666g、石韦999g、蒲公英666g、赤芍555g、夏枯草 666g、桔梗666g、生甘草555g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次2小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达70%,静置18小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入淀粉、低取代羟丙基纤维素适量,混匀,一步制粒,干燥,加入适量硬脂酸镁,混匀,压片,包衣,即得片剂。
实施例8
萹蓄555g、野菊花1110g、石韦555g、蒲公英1110g、赤芍333g、夏枯草 1110g、桔梗333g、生甘草1110g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加12倍量水提取1次,每次3小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达70%,静置24小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入乳糖、甘露醇适量,混匀,湿法制粒,干燥,加入适量硬脂酸镁,混匀,压片,包衣,即得片剂。
实施例9
萹蓄1665g、野菊花333g、石韦1665g、蒲公英333g、赤芍1110g、夏枯草 333g、桔梗1110g、生甘草333g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加8倍量水提取4次,每次0.5小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达70%,静置18小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入微晶纤维素、乳糖适量,混匀,湿法制粒,干燥,加入适量硬脂酸镁,混匀,压片,包衣,即得片剂。
实施例10
萹蓄333g、野菊花2220g、石韦333g、蒲公英2220g、赤芍111g、夏枯草 2220g、桔梗111g、生甘草2220g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~ 1.10,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入适量微晶纤维素、甘露醇,混匀,一步制粒,干燥,整粒,即得颗粒剂。
实施例11
萹蓄3330g、野菊花111g、石韦3330g、蒲公英111g、赤芍2220g、夏枯草 111g、桔梗2220g、生甘草111g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取2次,每次2小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达80%,静置18小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入羧甲基淀粉钠、微粉硅胶、微晶纤维素、交联聚维酮适量,混匀,一步制粒,干燥,加入适量硬脂酸镁,混匀,压片,包薄膜衣,即得片剂。
实施例12
萹蓄1332g、野菊花555g、石韦1332g、蒲公英555g、赤芍666g、夏枯草 555g、桔梗888g、生甘草444g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加9倍量水提取3次,每次2小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~ 1.10,离心,上清液继续浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,混匀,湿法制粒,干燥,装入胶囊,即得胶囊剂。
实施例13
萹蓄888g、野菊花888g、石韦888g、蒲公英888g、赤芍444g、夏枯草888g、桔梗555g、生甘草666g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加11倍量水提取2次,每次2.5小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达50%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入乳糖、甘露醇适量,混匀,湿法制粒,干燥,整粒,即得颗粒剂。
实施例14
萹蓄999g、野菊花777g、石韦999g、蒲公英666g、赤芍555g、夏枯草777g、桔梗777g、生甘草555g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次2小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达90%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入蔗糖、阿司帕坦,糊精适量,混匀,一步制粒,干燥,即得颗粒剂。
实施例15
萹蓄444g、野菊花1665g、石韦444g、蒲公英1665g、赤芍222g、夏枯草 1665g、桔梗222g、生甘草1665g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加12倍量水提取2次,每次1.5小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达60%,静置24小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,加入辅料适量,混匀,制成丸剂。
实施例16
萹蓄2220g、野菊花222g、石韦2220g、蒲公英333g、赤芍1221g、夏枯草222g、桔梗1665g、甘草333g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加9倍量水提取4次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~1.10,离心,上清液继续浓缩至稠膏,干燥,粉碎成细粉,制成散剂。
实施例17
萹蓄999g、野菊花777g、石韦888g、蒲公英555g、赤芍666g、夏枯草555g、桔梗555g、生甘草666g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取2次,每次3小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,加入凝胶基质、保湿剂、防腐剂,搅拌使溶解,放置,使充分溶胀,加溶剂调至全量,搅拌均匀,制成凝胶,即得凝胶剂。
实施例18
萹蓄1221g、野菊花555g、石韦1110g、蒲公英777g、赤芍444g、夏枯草 777g、桔梗777g、甘草444g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取2次,每次3小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,适当浓缩,加入适量的混悬剂、调味剂、防腐剂,混匀,加水定容,滤过,分装,即得口服液体制剂。
实施例19
萹蓄888g、野菊花1221g、石韦777g、蒲公英1332g、赤芍1221g、夏枯草 222g、桔梗444g、生甘草1221g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取2次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达80%,静置,滤过,滤液减压回收乙醇,适当浓缩得药液,备用;取硬脂酸、单硬脂酸甘油酯、十八醇、十六醇、轻质液状石蜡、中链脂肪酸甘油三酯(GTCC)、丁羟甲苯(BHT)适量,85℃加热熔融,作为油相;另取甘油、丙二醇、硬脂酸聚烃氧(40)酯、蔗糖硬脂酸酯S-15、三梨酸钾适量,加入药液和适量纯化水中溶解,加热至85℃,作为水相;将水相缓缓加入油相中,85℃保温乳化,转速为2000r/min,乳化15分钟后,继续搅拌冷却至40℃左右,搅拌15分钟,分装,即得软膏剂。
实施例20
萹蓄666g、野菊花777g、石韦1110g、蒲公英777g、赤芍888g、夏枯草 666g、桔梗222g、甘草888g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~1.15,加乙醇使含醇量达70%,静置,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,将稠膏粉、聚丙烯酸(NP-700)、氢氧化铝、氮酮加入甘油中搅拌均匀,再加入0.1%酒石酸水溶液,研磨均匀,涂于弹力布上,盖衬,分切,即得贴膏剂。
实施例21
萹蓄1221g、野菊花999g、石韦1221g、蒲公英444g、赤芍999g、夏枯草 444g、桔梗999g、生甘草444g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加9倍量水提取2次,每次2.5小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达90%,静置24小时,滤过,滤液减压回收乙醇至无醇味,适当浓缩,制成洗剂。
实施例22
萹蓄444g、野菊花1110g、石韦555g、蒲公英777g、赤芍666g、夏枯草 222g、桔梗999g、甘草555g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加8倍量水提取3次,每次2小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~1.10,离心,上清液继续浓缩至稠膏,加入适量辅料,制成栓剂。
实施例23
萹蓄1221g、野菊花999g、石韦1221g、蒲公英444g、赤芍999g、夏枯草 444g、桔梗999g、生甘草444g
萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、生甘草加10倍量水提取3次,每次2小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~ 1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,干燥,粉碎成细粉,备用;将基质加热熔融,加入上述细粉,搅匀,60-80℃保温,滴入冷凝介质中,待滴丸冷却后取出,沥净并擦除冷凝介质,即得滴丸剂。
通过以下实验进一步阐述本发明所述中药组合物的有益效果:
一、药理实验研究
1、实验材料
本发明中药组合物(实施例1)、Wister大鼠、昆明小鼠。
2、实验方法与结果
2.1抗菌试验
称取本发明中药组合物适量,加灭菌蒸馏水稀释备用。取各菌种接种营养琼脂平板,淋球菌接种巧克力色平板,白色念珠菌接种沙保氏琼脂平板。在各琼脂板上打孔,孔径5mm,取稀释试药加入各孔内,置37℃温箱内培养24小时,淋球菌置37℃CO2温箱内培养24小时,观察各琼脂平板上药物抑菌直径。结果见表1。
表1本发明中药组合物抑菌试验结果
结果表明,本发明中药组合物对所试菌株均具有不同程度的抑菌作用,其中对金黄色葡萄球菌、淋球菌的抑菌作用最强。
本发明实施例2-23进行了相似的抑菌试验,结果与上述结果相同。
2.2利尿试验
取大鼠30只,体重200±20g,雌雄各半,随机分为3组,用代谢笼法收集药前1小时尿液,随后灌胃给药或蒸馏水,收集每只大鼠药后1、2、3、4小时的尿液,结果见表2。
表2本发明中药组合物利尿试验结果
注:与空白对照组比较,*P<0.05,**P<0.01
结果表明,本发明中药组合物能明显增加给药后大鼠的尿量。
本发明实施例2-23进行了相似的利尿试验,结果与上述结果相同。
2.3镇痛试验
小鼠30只,雄性,体重18~22g,随机分为3组,每组10只。灌胃给药1 次。给药后1h,每只小鼠腹腔注射0.6%冰醋酸溶液0.2ml/只致痛,立即观察记录小鼠在20min内出现的扭体次数,结果见表3。
表3本发明中药组合物镇痛试验结果
注:与空白对照组比较,*P<0.05,**P<0.01
结果表明,本发明中药组合物能显著减少醋酸引起的扭体次数。
发明实施例2-23进行了相似的镇痛试验,结果与上述结果相同。
综上,本发明中药组合物具有抗菌、利尿、镇痛的作用。
二、临床观察
1、病例资料
下尿路感染患者共50例。其中治疗组30例,年龄20-65岁,病程2天-6周。治疗组与对照组年龄、性别、诊断、病情轻重、病程等分布基本一致,差异无统计学意义。
2、观察方法
2.1治疗方法
治疗组口服本发明中药组合物(实施例1),l日3次,2周为l个疗程。对照药采用国家基本药物中药制剂三金片,每次口服4片,l日3次,疗程与治疗组一致。
2.2疗效制定标准
分为近期治愈、显效、有效和无效。
近期治愈:临床症状、体征消失,尿常规检查3次均正常,尿菌检查连续2次以上阴性;
显效:临床症状、体征消失或基本消失,尿常规接近正常,尿菌阴性;
有效:临床症状、体征减轻,尿常规明显改善,尿培养偶有阳性;
无效:症状、体征及尿检无改善。
结果见表4。
表4本发明中药组合物治疗尿道炎与对照组疗效比较
结果表明,两组疗效经统计学处理,P<0.05,治疗组总有效率为90%,对照组总有效率为85%,表明治疗组疗效优于对照组,提示本发明中药组合物对治疗下尿路感染有很好的疗效。
Claims (5)
1.一种治疗下尿路感染的中药组合物,其特征在于,它是由下列重量份的原料药制成的:萹蓄5-15份、野菊花3-10份、石韦5-15份、蒲公英3-10份、赤芍3-10份、夏枯草3-10份、桔梗3-10份、甘草3-10份,所述中药组合物的制备方法为:
所述重量份的萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加8~12倍量水提取1~4次,每次0.5~3小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~1.15,加乙醇使含醇量达50~90%,静置,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,加入凝胶基质、保湿剂、防腐剂,搅拌使溶解,放置,使充分溶胀,加溶剂调至全量,搅拌均匀,制成凝胶剂;或,
所述重量份的萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加8~12倍量水提取1~4次,每次0.5~3小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~1.10,离心,上清液继续浓缩至稠膏,加入凝胶基质、保湿剂、防腐剂,搅拌使溶解,放置,使充分溶胀,加溶剂调至全量,搅拌均匀,制成凝胶剂。
2.根据权利要求1所述的中药组合物,其特征在于,所述中药组合物的制备方法为:
所述重量份的萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10~1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,加入凝胶基质、保湿剂、防腐剂,搅拌使溶解,放置,使充分溶胀,加溶剂调至全量,搅拌均匀,制成凝胶剂。
3.根据权利要求1所述的中药组合物,其特征在于,所述中药组合物的制备方法为:
所述重量份的萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取3次,每次1小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.05~1.10,离心,上清液继续浓缩至稠膏,加入凝胶基质、保湿剂、防腐剂,搅拌使溶解,放置,使充分溶胀,加溶剂调至全量,搅拌均匀,制成凝胶剂。
4.根据权利要求1所述的中药组合物,其特征在于,所述中药组合物的制备方法为:
所述重量份的萹蓄、野菊花、石韦、蒲公英、赤芍、夏枯草、桔梗、甘草加10倍量水提取2次,每次3小时,滤过,合并滤液,浓缩至60℃测时相对密度为1.10-1.15,加乙醇使含醇量达70%,静置12小时,滤过,滤液减压回收乙醇,浓缩至60℃测时相对密度为1.30~1.35的稠膏,加入凝胶基质、保湿剂、防腐剂,搅拌使溶解,放置,使充分溶胀,加溶剂调至全量,搅拌均匀,制成凝胶剂。
5.根据权利要求1-4任一项所述的中药组合物,其特征在于,所述中药组合物在制备治疗下尿路感染药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810211920.6A CN108210575B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物凝胶剂的制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810211920.6A CN108210575B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物凝胶剂的制备方法 |
CN201310413521.5A CN104435157B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物及其制备方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310413521.5A Division CN104435157B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108210575A true CN108210575A (zh) | 2018-06-29 |
CN108210575B CN108210575B (zh) | 2021-05-07 |
Family
ID=52882419
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810211944.1A Active CN108186743B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物胶囊剂的制备方法 |
CN201810212275.XA Active CN108295123B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物片剂的制备方法 |
CN201810212001.0A Active CN108186747B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物颗粒剂的制备方法 |
CN201310413521.5A Active CN104435157B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物及其制备方法 |
CN201810212273.0A Active CN108272868B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物软膏剂的制备方法 |
CN201810212274.5A Active CN108272869B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物口服液体制剂的制备方法 |
CN201810211920.6A Active CN108210575B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物凝胶剂的制备方法 |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810211944.1A Active CN108186743B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物胶囊剂的制备方法 |
CN201810212275.XA Active CN108295123B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物片剂的制备方法 |
CN201810212001.0A Active CN108186747B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物颗粒剂的制备方法 |
CN201310413521.5A Active CN104435157B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物及其制备方法 |
CN201810212273.0A Active CN108272868B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物软膏剂的制备方法 |
CN201810212274.5A Active CN108272869B (zh) | 2013-09-12 | 2013-09-12 | 一种治疗下尿路感染的中药组合物口服液体制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (7) | CN108186743B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115300470B (zh) * | 2022-08-26 | 2023-07-25 | 雅安迅康药业有限公司 | 一种夏枯草片及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101559144A (zh) * | 2008-04-17 | 2009-10-21 | 王守东 | 一种治疗尿道炎,膀胱炎及急、慢性肾盂肾炎的口服药通淋护肾胶囊及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2098119C1 (ru) * | 1996-05-21 | 1997-12-10 | Научно-производственное объединение "Всероссийский научно-исследовательский институт лекарственных и ароматических растений" | Лечебно-профилактическое средство "простанорм" для лечения простатитов, уретритов и других воспалительных заболеваний мочеполовой сферы |
US6143300A (en) * | 1998-08-11 | 2000-11-07 | Robin Ann Stevenot | Fem-Ease, a supplement for the symptoms of cystitis, urinary tract infections and premenstrual syndrome |
CN101049365A (zh) * | 2007-05-16 | 2007-10-10 | 北京艺信堂医药研究所 | 一种治疗非淋菌性尿道炎的中药制剂 |
-
2013
- 2013-09-12 CN CN201810211944.1A patent/CN108186743B/zh active Active
- 2013-09-12 CN CN201810212275.XA patent/CN108295123B/zh active Active
- 2013-09-12 CN CN201810212001.0A patent/CN108186747B/zh active Active
- 2013-09-12 CN CN201310413521.5A patent/CN104435157B/zh active Active
- 2013-09-12 CN CN201810212273.0A patent/CN108272868B/zh active Active
- 2013-09-12 CN CN201810212274.5A patent/CN108272869B/zh active Active
- 2013-09-12 CN CN201810211920.6A patent/CN108210575B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101559144A (zh) * | 2008-04-17 | 2009-10-21 | 王守东 | 一种治疗尿道炎,膀胱炎及急、慢性肾盂肾炎的口服药通淋护肾胶囊及其制备方法 |
Non-Patent Citations (1)
Title |
---|
佚名: "苏大夫处方", 《家庭医药》 * |
Also Published As
Publication number | Publication date |
---|---|
CN108186747A (zh) | 2018-06-22 |
CN108210575B (zh) | 2021-05-07 |
CN104435157A (zh) | 2015-03-25 |
CN104435157B (zh) | 2018-05-01 |
CN108295123B (zh) | 2021-05-11 |
CN108186743B (zh) | 2021-05-11 |
CN108295123A (zh) | 2018-07-20 |
CN108186747B (zh) | 2020-11-24 |
CN108272868B (zh) | 2021-05-11 |
CN108272869A (zh) | 2018-07-13 |
CN108186743A (zh) | 2018-06-22 |
CN108272869B (zh) | 2021-04-06 |
CN108272868A (zh) | 2018-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6031662B2 (ja) | 認知機能低下改善用組成物 | |
CN102836228B (zh) | 一种治疗结膜炎的中药组合物及其制备方法和应用 | |
CN102205026A (zh) | 一种治疗小儿慢性鼻窦炎的中药组合物及其制备方法 | |
CN107343868A (zh) | 一种具有祛湿疹功能的组合物及其制备方法 | |
CN104435157B (zh) | 一种治疗下尿路感染的中药组合物及其制备方法 | |
EP3141256B1 (en) | Hepatoprotective traditional chinese medicine composition, and preparation method thereof | |
CN104958633A (zh) | 一种治疗寻常性痤疮的药物及其制备方法 | |
CN105641014B (zh) | 南天竹总生物碱提取物及其在制备治疗咽炎药物中的应用 | |
CN103191167A (zh) | 华泽兰的应用 | |
CN103961455A (zh) | 一种清热解毒的中药复方制剂及其制备方法 | |
CN109568519A (zh) | 一种用于湿疹的中药组合物及其制备方法 | |
CN102940679A (zh) | 治疗痔疮的中药组合物及其制备方法 | |
CN113304218B (zh) | 治疗猫杯状病毒感染的中药 | |
CN111759901B (zh) | 一种治疗儿童功能性腹痛的中药组合物及其制备方法 | |
CN101244170B (zh) | 用于治疗小儿外感咳嗽的药物及制备方法 | |
CN103656252B (zh) | 一种治疗女性尿道疾病的中药组合物及其制备方法 | |
CN108938785B (zh) | 一种治疗咳嗽变异性哮喘的中药组合物及其制备方法 | |
CN105617175B (zh) | 一种治疗妇科疾病的中药组合物及其制备方法 | |
CN105012391B (zh) | 一种治疗病毒性感冒的药物及其制作方法 | |
CN117159659A (zh) | 一种治疗湿疹的中药组合物及其制备方法与应用 | |
CN113018396A (zh) | 一种治疗复发性泌尿道感染的中药组合物及其制备方法 | |
CN116440210A (zh) | 用于糖尿病足治疗的中药组合物及用途 | |
CN112587590A (zh) | 一种治疗风湿性关节炎的中药组合物及其制备方法 | |
CN112043785A (zh) | 一种外用中药抗生素贴膏的制备方法 | |
CN115645486A (zh) | 一种清热降火的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |